Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001964955 | SCV002199927 | uncertain significance | Capillary malformation-arteriovenous malformation syndrome | 2021-07-21 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with RASA1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces lysine with glutamic acid at codon 118 of the RASA1 protein (p.Lys118Glu). The lysine residue is weakly conserved and there is a small physicochemical difference between lysine and glutamic acid. |
Ambry Genetics | RCV002458829 | SCV002616142 | uncertain significance | Cardiovascular phenotype | 2022-07-08 | criteria provided, single submitter | clinical testing | The p.K118E variant (also known as c.352A>G), located in coding exon 1 of the RASA1 gene, results from an A to G substitution at nucleotide position 352. The lysine at codon 118 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |